New combo therapy targets rare abdominal cancer
NCT ID NCT03875144
First seen Feb 15, 2026 · Last updated Jun 12, 2026 · Updated 23 times
Summary
This study tests whether adding a special chemotherapy spray (PIPAC) directly into the abdomen to standard IV chemo can help people with a rare cancer of the belly lining (peritoneal mesothelioma) live longer. About 66 adults who have not had prior treatment will be randomly assigned to receive either standard chemo alone or standard chemo plus PIPAC. The trial is currently suspended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERITONEAL CARCINOMATOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut réginal du Cancer de Montpellier
Montpellier, 34298, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.